Ptc Therapeutics (PTCT) Receivables - Net (2013 - 2026)

Ptc Therapeutics' Receivables - Net history runs 14 years deep, the most recent figure standing at $239.0 million for Q2 2026.

• In Q2 2026, Receivables - Net rose 21.88% year-over-year to $239.0 million; the TTM figure through Jun 2026 stood at $239.0 million (up 21.88% YoY), while the FY2025 annual figure was $181.6 million, up 14.55% from the prior year.
• Receivables - Net for Q2 2026 stood at $239.0 million, up from $219.9 million in the prior quarter.
• The five-year high for Receivables - Net was $239.0 million in Q2 2026, with the low at $124.5 million in Q3 2022.
• The 5-year median for Receivables - Net is $184.4 million (2024), against an average of $180.9 million.
• The sharpest annual moves came in 2022 and 2024: Receivables - Net soared 72.51% in 2022, then dropped 2.08% in 2024.
• Ptc Therapeutics' Receivables - Net stood at $155.6 million in 2022, then gained by 3.35% to $160.8 million in 2023, then slipped by 1.41% to $158.6 million in 2024, then rose by 14.55% to $181.6 million in 2025, then jumped by 31.62% to $239.0 million in 2026.
• Business Quant data shows PTCT's Receivables - Net at $239.0 million in Q2 2026, $219.9 million in Q1 2026, and $181.6 million in Q4 2025.